[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUs1AQa9VgNHnUwvPqgfGFk1dTtsWFtoW_Kef_beAaDw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Drexel University",[4,6],"Drexel University College of Medicine",143,false,25,4,15100,0,119,[15,18,21,23,26,28,31,33],{"name":16,"count":17},"Obesity",20,{"name":19,"count":20},"Bulimia Nervosa",11,{"name":22,"count":20},"Overweight",{"name":24,"count":25},"Binge Eating",10,{"name":27,"count":25},"Amyotrophic Lateral Sclerosis",{"name":29,"count":30},"Binge-Eating Disorder",9,{"name":32,"count":30},"Neurodegenerative Disease",{"name":34,"count":30},"Motor Neuron Disease",[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,71,97,115,142,168,194,220,238,289,320,345,363,381,399,417,435,453,476,499,525,549,574,592,610,628,646,664,682,710,735,760,793,815,839,861],{"intervention":45,"totalTrials":46,"cells":47},"Levetiracetam",1,{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":69},{"trials":49,"activeCount":12},[],{"trials":51,"activeCount":12},[],{"trials":53,"activeCount":12},[],{"trials":55,"activeCount":12},[],{"trials":57,"activeCount":12},[58],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":68},"NCT01318408","Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia","COMPLETED",[41],"2008-03","2006-11",24,[67],"Epilepsy",[45],{"trials":70,"activeCount":12},[],{"intervention":72,"totalTrials":46,"cells":73},"ketamine and midazolam",{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":82,"NA":95},{"trials":75,"activeCount":12},[],{"trials":77,"activeCount":12},[],{"trials":79,"activeCount":12},[],{"trials":81,"activeCount":12},[],{"trials":83,"activeCount":12},[84],{"nctId":85,"briefTitle":86,"status":61,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT00596050","Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions",[41],"2008-06","2006-08",50,[92],"Conscious Sedation Failure During Procedure",[72,94],"etomidate, fentanyl, and lidocaine",{"trials":96,"activeCount":12},[],{"intervention":94,"totalTrials":46,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":113},{"trials":100,"activeCount":12},[],{"trials":102,"activeCount":12},[],{"trials":104,"activeCount":12},[],{"trials":106,"activeCount":12},[],{"trials":108,"activeCount":12},[109],{"nctId":85,"briefTitle":86,"status":61,"phases":110,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":111,"interventions":112},[41],[92],[72,94],{"trials":114,"activeCount":12},[],{"intervention":116,"totalTrials":46,"cells":117},"Lithium",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":138,"NA":140},{"trials":119,"activeCount":12},[],{"trials":121,"activeCount":12},[],{"trials":123,"activeCount":12},[],{"trials":125,"activeCount":12},[126],{"nctId":127,"briefTitle":128,"status":61,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":137},"NCT00000385","Long-Term Lithium Treatment for Aggressive Conduct Disorder",[40],"2003-12","2005-06","1997-09",59,[135,136],"Conduct Disorder","Aggression",[116],{"trials":139,"activeCount":12},[],{"trials":141,"activeCount":12},[],{"intervention":143,"totalTrials":46,"cells":144},"basiliximab",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":164,"NA":166},{"trials":146,"activeCount":12},[],{"trials":148,"activeCount":12},[],{"trials":150,"activeCount":12},[],{"trials":152,"activeCount":12},[153],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT00928811","Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant","TERMINATED",[39,40],"2010-04","2009-05",5,[162],"End Stage Renal Disease",[143,143],{"trials":165,"activeCount":12},[],{"trials":167,"activeCount":12},[],{"intervention":169,"totalTrials":46,"cells":170},"Olanzapine",{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":190,"NA":192},{"trials":172,"activeCount":12},[],{"trials":174,"activeCount":12},[],{"trials":176,"activeCount":12},[],{"trials":178,"activeCount":12},[179],{"nctId":180,"briefTitle":181,"status":61,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT00183404","Long-Term Olanzapine Treatment in Children With Autism",[39,40],"2011-07","2011-10","2004-09",32,[188],"Autism",[169],{"trials":191,"activeCount":12},[],{"trials":193,"activeCount":12},[],{"intervention":195,"totalTrials":46,"cells":196},"Methylnaltrexone",{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":216,"NA":218},{"trials":198,"activeCount":12},[],{"trials":200,"activeCount":12},[],{"trials":202,"activeCount":12},[],{"trials":204,"activeCount":12},[205],{"nctId":206,"briefTitle":207,"status":208,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":12,"conditions":212,"interventions":214},"NCT01360372","Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates","WITHDRAWN",[40],"2012-05","2010-10",[213],"Tube Feeding",[195,215],"Saline",{"trials":217,"activeCount":12},[],{"trials":219,"activeCount":12},[],{"intervention":215,"totalTrials":46,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":234,"NA":236},{"trials":223,"activeCount":12},[],{"trials":225,"activeCount":12},[],{"trials":227,"activeCount":12},[],{"trials":229,"activeCount":12},[230],{"nctId":206,"briefTitle":207,"status":208,"phases":231,"primaryCompletion":210,"completion":210,"start":211,"enrollment":12,"conditions":232,"interventions":233},[40],[213],[195,215],{"trials":235,"activeCount":12},[],{"trials":237,"activeCount":12},[],{"intervention":239,"totalTrials":240,"cells":241},"filgrastim",2,{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":243,"activeCount":12},[],{"trials":245,"activeCount":12},[],{"trials":247,"activeCount":12},[248,266],{"nctId":249,"briefTitle":250,"status":61,"phases":251,"completion":252,"start":253,"conditions":254,"interventions":259},"NCT00003619","Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia",[38,39],"2004-04","1998-02",[255,256,257,258],"Chronic Myeloproliferative Disorders","Leukemia","Myelodysplastic Syndromes","Thrombocytopenia",[239,260,261,262,263,264,265],"busulfan","cytarabine","etoposide","fludarabine phosphate","isotretinoin","topotecan hydrochloride",{"nctId":267,"briefTitle":268,"status":61,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":273,"interventions":275},"NCT01467115","Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer",[39],"2014-06","2014-10-07","2010-03",[274],"Head and Neck Cancer",[276,277,278,279,280,281,282],"Leucovorin","Cetuximab","Filgrastim","Erythropoetin","Cisplatin","Fluorouracil","Docetaxel",{"trials":284,"activeCount":12},[],{"trials":286,"activeCount":12},[],{"trials":288,"activeCount":12},[],{"intervention":290,"totalTrials":240,"cells":291},"PRO 140",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":293,"activeCount":12},[],{"trials":295,"activeCount":12},[],{"trials":297,"activeCount":12},[298,307],{"nctId":299,"briefTitle":300,"status":208,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":12,"conditions":304,"interventions":306},"NCT02438345","PRO 140 for Human Immunodeficiency Virus",[39],"2015-02","2012-11",[305],"HIV",[290],{"nctId":308,"briefTitle":309,"status":208,"phases":310,"primaryCompletion":302,"completion":302,"start":311,"enrollment":12,"conditions":312,"interventions":313},"NCT02257788","PRO 140 for Human Immunodeficiency Virus Infection",[39],"2014-09",[305],[290],{"trials":315,"activeCount":12},[],{"trials":317,"activeCount":12},[],{"trials":319,"activeCount":12},[],{"intervention":321,"totalTrials":46,"cells":322},"Rapamycin",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":339,"PHASE4":341,"NA":343},{"trials":324,"activeCount":12},[],{"trials":326,"activeCount":12},[],{"trials":328,"activeCount":12},[329],{"nctId":330,"briefTitle":331,"status":61,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT03103893","Novel Compositions for Treating or Preventing Dermal Disorders",[38,39],"2017-11-30","2017-09-25",36,[337],"Dermal Atrophy",[321],{"trials":340,"activeCount":12},[],{"trials":342,"activeCount":12},[],{"trials":344,"activeCount":12},[],{"intervention":260,"totalTrials":46,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":348,"activeCount":12},[],{"trials":350,"activeCount":12},[],{"trials":352,"activeCount":12},[353],{"nctId":249,"briefTitle":250,"status":61,"phases":354,"completion":252,"start":253,"conditions":355,"interventions":356},[38,39],[255,256,257,258],[239,260,261,262,263,264,265],{"trials":358,"activeCount":12},[],{"trials":360,"activeCount":12},[],{"trials":362,"activeCount":12},[],{"intervention":261,"totalTrials":46,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":366,"activeCount":12},[],{"trials":368,"activeCount":12},[],{"trials":370,"activeCount":12},[371],{"nctId":249,"briefTitle":250,"status":61,"phases":372,"completion":252,"start":253,"conditions":373,"interventions":374},[38,39],[255,256,257,258],[239,260,261,262,263,264,265],{"trials":376,"activeCount":12},[],{"trials":378,"activeCount":12},[],{"trials":380,"activeCount":12},[],{"intervention":262,"totalTrials":46,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":384,"activeCount":12},[],{"trials":386,"activeCount":12},[],{"trials":388,"activeCount":12},[389],{"nctId":249,"briefTitle":250,"status":61,"phases":390,"completion":252,"start":253,"conditions":391,"interventions":392},[38,39],[255,256,257,258],[239,260,261,262,263,264,265],{"trials":394,"activeCount":12},[],{"trials":396,"activeCount":12},[],{"trials":398,"activeCount":12},[],{"intervention":263,"totalTrials":46,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":402,"activeCount":12},[],{"trials":404,"activeCount":12},[],{"trials":406,"activeCount":12},[407],{"nctId":249,"briefTitle":250,"status":61,"phases":408,"completion":252,"start":253,"conditions":409,"interventions":410},[38,39],[255,256,257,258],[239,260,261,262,263,264,265],{"trials":412,"activeCount":12},[],{"trials":414,"activeCount":12},[],{"trials":416,"activeCount":12},[],{"intervention":264,"totalTrials":46,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":420,"activeCount":12},[],{"trials":422,"activeCount":12},[],{"trials":424,"activeCount":12},[425],{"nctId":249,"briefTitle":250,"status":61,"phases":426,"completion":252,"start":253,"conditions":427,"interventions":428},[38,39],[255,256,257,258],[239,260,261,262,263,264,265],{"trials":430,"activeCount":12},[],{"trials":432,"activeCount":12},[],{"trials":434,"activeCount":12},[],{"intervention":265,"totalTrials":46,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":438,"activeCount":12},[],{"trials":440,"activeCount":12},[],{"trials":442,"activeCount":12},[443],{"nctId":249,"briefTitle":250,"status":61,"phases":444,"completion":252,"start":253,"conditions":445,"interventions":446},[38,39],[255,256,257,258],[239,260,261,262,263,264,265],{"trials":448,"activeCount":12},[],{"trials":450,"activeCount":12},[],{"trials":452,"activeCount":12},[],{"intervention":454,"totalTrials":46,"cells":455},"Aripiprazole",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":457,"activeCount":12},[],{"trials":459,"activeCount":12},[],{"trials":461,"activeCount":12},[462],{"nctId":463,"briefTitle":464,"status":61,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":20,"conditions":468,"interventions":469},"NCT00208533","Aripiprazole in Children With Autism: A Pilot Study",[39],"2011-11-16","2004-02",[188],[454],{"trials":471,"activeCount":12},[],{"trials":473,"activeCount":12},[],{"trials":475,"activeCount":12},[],{"intervention":477,"totalTrials":46,"cells":478},"Ziprasidone",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":480,"activeCount":12},[],{"trials":482,"activeCount":12},[],{"trials":484,"activeCount":12},[485],{"nctId":486,"briefTitle":487,"status":61,"phases":488,"primaryCompletion":131,"completion":89,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT00208559","Ziprasidone in Children With Autism: A Pilot Study",[39],"2002-02",15,[188],[477],{"trials":494,"activeCount":12},[],{"trials":496,"activeCount":12},[],{"trials":498,"activeCount":12},[],{"intervention":500,"totalTrials":46,"cells":501},"Ketamine",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":503,"activeCount":12},[],{"trials":505,"activeCount":12},[],{"trials":507,"activeCount":12},[508],{"nctId":509,"briefTitle":510,"status":61,"phases":511,"primaryCompletion":512,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT00579085","Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS",[39],"2008-09","2009-11","2006-09",40,[517],"Complex Regional Pain Syndrome",[500],{"trials":520,"activeCount":12},[],{"trials":522,"activeCount":12},[],{"trials":524,"activeCount":12},[],{"intervention":526,"totalTrials":46,"cells":527},"MAb-425",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":529,"activeCount":12},[],{"trials":531,"activeCount":12},[],{"trials":533,"activeCount":12},[534],{"nctId":535,"briefTitle":536,"status":61,"phases":537,"primaryCompletion":538,"completion":538,"start":539,"enrollment":20,"conditions":540,"interventions":542},"NCT00589706","A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas",[39],"2012-12","1985-01",[541],"Gliomas",[526],{"trials":544,"activeCount":12},[],{"trials":546,"activeCount":12},[],{"trials":548,"activeCount":12},[],{"intervention":550,"totalTrials":46,"cells":551},"lidocaine",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":553,"activeCount":12},[],{"trials":555,"activeCount":12},[],{"trials":557,"activeCount":12},[558],{"nctId":559,"briefTitle":560,"status":156,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT03117166","Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing",[38,39],"2010-05","2010-01",19,[566],"Pain",[550],{"trials":569,"activeCount":12},[],{"trials":571,"activeCount":12},[],{"trials":573,"activeCount":12},[],{"intervention":276,"totalTrials":46,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":577,"activeCount":12},[],{"trials":579,"activeCount":12},[],{"trials":581,"activeCount":12},[582],{"nctId":267,"briefTitle":268,"status":61,"phases":583,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":584,"interventions":585},[39],[274],[276,277,278,279,280,281,282],{"trials":587,"activeCount":12},[],{"trials":589,"activeCount":12},[],{"trials":591,"activeCount":12},[],{"intervention":277,"totalTrials":46,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":604,"PHASE4":606,"NA":608},{"trials":595,"activeCount":12},[],{"trials":597,"activeCount":12},[],{"trials":599,"activeCount":12},[600],{"nctId":267,"briefTitle":268,"status":61,"phases":601,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":602,"interventions":603},[39],[274],[276,277,278,279,280,281,282],{"trials":605,"activeCount":12},[],{"trials":607,"activeCount":12},[],{"trials":609,"activeCount":12},[],{"intervention":279,"totalTrials":46,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":613,"activeCount":12},[],{"trials":615,"activeCount":12},[],{"trials":617,"activeCount":12},[618],{"nctId":267,"briefTitle":268,"status":61,"phases":619,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":620,"interventions":621},[39],[274],[276,277,278,279,280,281,282],{"trials":623,"activeCount":12},[],{"trials":625,"activeCount":12},[],{"trials":627,"activeCount":12},[],{"intervention":280,"totalTrials":46,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":631,"activeCount":12},[],{"trials":633,"activeCount":12},[],{"trials":635,"activeCount":12},[636],{"nctId":267,"briefTitle":268,"status":61,"phases":637,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":638,"interventions":639},[39],[274],[276,277,278,279,280,281,282],{"trials":641,"activeCount":12},[],{"trials":643,"activeCount":12},[],{"trials":645,"activeCount":12},[],{"intervention":281,"totalTrials":46,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":649,"activeCount":12},[],{"trials":651,"activeCount":12},[],{"trials":653,"activeCount":12},[654],{"nctId":267,"briefTitle":268,"status":61,"phases":655,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":656,"interventions":657},[39],[274],[276,277,278,279,280,281,282],{"trials":659,"activeCount":12},[],{"trials":661,"activeCount":12},[],{"trials":663,"activeCount":12},[],{"intervention":282,"totalTrials":46,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":667,"activeCount":12},[],{"trials":669,"activeCount":12},[],{"trials":671,"activeCount":12},[672],{"nctId":267,"briefTitle":268,"status":61,"phases":673,"primaryCompletion":270,"completion":271,"start":272,"enrollment":46,"conditions":674,"interventions":675},[39],[274],[276,277,278,279,280,281,282],{"trials":677,"activeCount":12},[],{"trials":679,"activeCount":12},[],{"trials":681,"activeCount":12},[],{"intervention":683,"totalTrials":46,"cells":684},"Vancomycin",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":686,"activeCount":12},[],{"trials":688,"activeCount":12},[689],{"nctId":690,"briefTitle":691,"status":692,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":25,"conditions":697,"interventions":701},"NCT02663596","Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution","UNKNOWN",[38],"2021-12","2022-12","2017-01",[698,699,700],"Pediatric Continuous Renal Replacement Therapy","Dialysis","Renal Failure",[683],{"trials":703,"activeCount":12},[],{"trials":705,"activeCount":12},[],{"trials":707,"activeCount":12},[],{"trials":709,"activeCount":12},[],{"intervention":711,"totalTrials":46,"cells":712},"Mitochondrial Cocktail",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":727,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":714,"activeCount":12},[],{"trials":716,"activeCount":12},[717],{"nctId":718,"briefTitle":719,"status":692,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":90,"conditions":723,"interventions":726},"NCT02348125","Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?",[38],"2017-06","2016-03",[724,725],"Autism Spectrum Disorders","Mitochondrial Diseases",[711],{"trials":728,"activeCount":12},[],{"trials":730,"activeCount":12},[],{"trials":732,"activeCount":12},[],{"trials":734,"activeCount":12},[],{"intervention":736,"totalTrials":46,"cells":737},"Cefazolin",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":739,"activeCount":12},[],{"trials":741,"activeCount":12},[742],{"nctId":743,"briefTitle":744,"status":692,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":17,"conditions":748,"interventions":751},"NCT03672149","Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy",[38],"2022-12-31","2019-07-18",[749,750],"Renal Replacement Therapy","Pharmacokinetics",[736],{"trials":753,"activeCount":12},[],{"trials":755,"activeCount":12},[],{"trials":757,"activeCount":12},[],{"trials":759,"activeCount":12},[],{"intervention":761,"totalTrials":240,"cells":762},"Aprepitant",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":764,"activeCount":12},[],{"trials":766,"activeCount":12},[],{"trials":768,"activeCount":12},[],{"trials":770,"activeCount":12},[],{"trials":772,"activeCount":12},[],{"trials":774,"activeCount":12},[775,786],{"nctId":776,"briefTitle":777,"status":61,"phases":778,"primaryCompletion":272,"completion":272,"start":779,"enrollment":780,"conditions":781,"interventions":784},"NCT00717054","Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting",[42],"2008-02",115,[782,783],"Nausea","Vomiting",[761,785],"Scopolamine",{"nctId":787,"briefTitle":788,"status":61,"phases":789,"primaryCompletion":272,"completion":272,"start":790,"enrollment":780,"conditions":791,"interventions":792},"NCT00659737","Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting",[42],"2008-04",[782,783],[761,785],{"intervention":785,"totalTrials":240,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":796,"activeCount":12},[],{"trials":798,"activeCount":12},[],{"trials":800,"activeCount":12},[],{"trials":802,"activeCount":12},[],{"trials":804,"activeCount":12},[],{"trials":806,"activeCount":12},[807,811],{"nctId":776,"briefTitle":777,"status":61,"phases":808,"primaryCompletion":272,"completion":272,"start":779,"enrollment":780,"conditions":809,"interventions":810},[42],[782,783],[761,785],{"nctId":787,"briefTitle":788,"status":61,"phases":812,"primaryCompletion":272,"completion":272,"start":790,"enrollment":780,"conditions":813,"interventions":814},[42],[782,783],[761,785],{"intervention":816,"totalTrials":46,"cells":817},"Rifampicin 600 mg",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":826,"NA":828},{"trials":819,"activeCount":12},[],{"trials":821,"activeCount":12},[],{"trials":823,"activeCount":12},[],{"trials":825,"activeCount":12},[],{"trials":827,"activeCount":12},[],{"trials":829,"activeCount":12},[830],{"nctId":831,"briefTitle":832,"status":61,"phases":833,"primaryCompletion":722,"completion":834,"start":270,"enrollment":835,"conditions":836,"interventions":838},"NCT01845298","Immune Activation and Drug Absorption in HIV-Infected Patients",[42],"2016-03-14",7,[837],"HIV Infection",[816],{"intervention":840,"totalTrials":46,"cells":841},"Depodur",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":843,"activeCount":12},[],{"trials":845,"activeCount":12},[],{"trials":847,"activeCount":12},[],{"trials":849,"activeCount":12},[],{"trials":851,"activeCount":12},[],{"trials":853,"activeCount":12},[854],{"nctId":855,"briefTitle":856,"status":208,"phases":857,"primaryCompletion":790,"completion":790,"start":790,"enrollment":12,"conditions":858,"interventions":860},"NCT00456638","Clinical Study of Depodur Efficacy in Decreasing Post Operative Pain After Off Pump Coronary Artery Bypass Grafting (OP-CABG)",[42],[859],"Pain, Postoperative",[840],{"intervention":862,"totalTrials":46,"cells":863},"MAB-425 radiolabeled with I-125",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":865,"activeCount":12},[],{"trials":867,"activeCount":12},[],{"trials":869,"activeCount":12},[],{"trials":871,"activeCount":12},[],{"trials":873,"activeCount":12},[],{"trials":875,"activeCount":12},[876],{"nctId":877,"briefTitle":878,"status":692,"phases":879,"primaryCompletion":880,"start":563,"enrollment":20,"conditions":881,"interventions":884},"NCT01317888","Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas",[42],"2014-01",[882,883],"Glioblastoma Multiforme","Astrocytoma Anaplastic Foci",[862]]